Alight and eMed join forces to expand access to GLP-1 therapies for employers, advancing population and workforce health. DEERFIELD, Ill.-(BUSINESS WIRE)-Alight, Inc. (NYSE: ALIT), a leading benefits administration provider of health, wealth and leave solutions, today announced the addition of eMed Population Health, Inc., a platform for employer-sponsored preventative health management, to the Alight Partner Network. The collaboration will enhance employer-sponsored access to GLP-1 therapies and give organizations a scalable way to support eligible employees, improve adherence to treatment and address the cost and complexity of weight management benefits. The groundswell of interest in GLP-1 medications among the general population has soared in recent years - 11% of U.S. adults now take GLP-1 medications for weight loss, up from 3% in 2024, according to Gallup's National Health and Well-Being Index. As demand for obesity and chronic condition management continues to rise, employers are seeking solutions that foster long-term workforce health while helping manage healthcare costs. By adding eMed to its Partner Network, Alight is expanding its health ecosystem with an industry-leading, flexible, outcomes-focused GLP-1 solution designed to support employers across a range of workforce health goals, benefits strategies and coverage approaches. Through a connected experience that includes clinical evaluation, treatment access, adherence support and ongoing engagement, organizations can provide eligible employees with personalized care, regardless of their coverage needs, while gaining greater visibility into utilization and outcomes. "Employers are looking for smarter, more sustainable ways to address rising healthcare costs while improving outcomes for their people," said Jessica Borchik, SVP, Partner Strategy and Sales at Alight. "By welcoming eMed into our Partner Network, we're expanding access to a clinically rigorous, outcomes-focused approach to GLP-1 management that helps organizations support employee health while maintaining cost control." The collaboration reflects a shared commitment to helping employers, including Fortune 500 companies already supported by Alight, implement GLP-1 programs that align with their unique needs while improving health outcomes and managing costs. "We're at a pivotal moment in healthcare where employers have an opportunity to fundamentally change the trajectory of population health and chronic diseases," said Greg Page, SVP Partnerships & Strategy at eMed. "By partnering with Alight, we're combining access and accountability in a way that helps organizations improve employee health, manage costs, and realize the full promise of GLP-1 therapies." Together, Alight and eMed will provide employers with a scalable way to manage utilization, improve adherence and reduce avoidable healthcare spend while delivering a more connected and personalized health experience for eligible employees. About Alight Solutions Alight is a leading benefits administration provider of health, wealth, leave and point solutions for many of the world's largest organizations and over 30 million people. Through the administration of employee benefits, Alight helps clients gain a benefits advantage while building a health and financially secure workforce by unifying the benefits ecosystem across health, wealth, wellbeing, absence management and navigation. Its Alight Worklife(R) platform empowers employers to gain a deeper understanding of their workforce and engage them throughout life's most important moments with personalized benefits management and data-driven insights, leading to increased employee wellbeing, engagement and productivity. Learn more at alight.com. About eMed eMed is the world's first end-to-end GLP-1 care platform built on Empathetic AI(TM). From remote diagnostics and clinician-led prescriptions to adherence coaching and insights, eMed empowers employers to manage population health with accountability and compassion. Learn more at www.eMed.com.

NFL legend Tom Brady has partnered with digital health company eMed as chief wellness officer to expand access to GLP-1 weight loss medications. The collaboration aims to incentivise employers to cover these drugs for eligible workers whilst reducing health insurance claims. Brady said the partnership addresses America's obesity epidemic by "democratising health and wellness in a way that the world has never seen". With more than 60% of Americans receiving health benefits through employers, eMed targets companies to provide coverage for GLP-1 medications. eMed CEO Linda Yaccarino called GLP-1 drugs a "pharmaceutical revolution", noting the programme combines AI, technology, and clinical support. The initiative offers both health benefits for employees and financial advantages for employers covering the medications.

Crux, eMed partner to expand employer access to GLP-1 medications. The collaboration aims to help employees access FDA-approved GLP-1s alongside clinical care, prescribing support, and payment and pharmacy fulfillment. Specialty employee benefits platform Crux announced a strategic collaboration with telehealth and digital health company eMed to improve employees' access to GLP-1 medications. Miami-based eMed, whose founding chief wellness officer is former NFL quarterback Tom Brady, offers an individual and employee health benefit platform that provides access to GLP-1 medications, at-home blood testing and a care package for common side effects of GLP-1s. Crux works with employers, individuals, brokers and consultants to offer benefits packages aimed at improving individuals' access to medication, including pharmacy fulfillment and home delivery. The partnership will combine eMed's clinical care model, including clinician evaluation and prescribing support, with Crux's payment and fulfillment infrastructure, which facilitates employers' tax-advantaged health reimbursement arrangement (HRA) contributions for employees, to help them access prescriptions, including FDA-approved GLP-1 medications. Members will have access to continuous clinical support through eMed, including dose adjustments, coaching and regular check-ins. "This partnership represents a pivotal step toward a future where healthcare is no longer reactive, but continuous, proactive and deeply personal," eMed CEO Linda Yaccarino said in a statement. "While GLP-1s are a powerful catalyst, they open the door to reimagining how clinical care, technology and benefits converge to drive better outcomes at scale. Together with Crux, we're enabling employers to lead that transformation while empowering people to take greater control of their health and their future." THE LARGER TREND Earlier this year, eMed closed a $200 million Series A funding round at a more than $2 billion valuation. In August 2025, the company's CEO, Yaccarino, joined eMed after serving for two years as CEO of Elon Musk-owned social media platform X, formerly Twitter. Prior to X, Yaccarino served as an NBCUniversal ad sales executive. A month later, X's former global head of strategic partners, Amy Elkins, joined eMed as chief operating officer. eMed announced a partnership with Arianna Huffington's behavioral-change technology platform, Thrive Global, to offer an end-to-end obesity-care program for employers. The offering combined eMed's clinical platform for GLP-1 and GIP medications with Thrive's behavior change and lifestyle offerings. eMed first launched in the fall of 2020 as a digital health company focused on at-home rapid COVID-19 testing through a collaboration with pharma giant Abbott. The company subsequently offered Urgent Care Telehealth Kits for at-home testing of COVID, influenza, strep throat and urinary tract infections, and has since pivoted to become a GLP-1-focused and AI-enabled weight-management platform.